M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma
M He, Y Wang, J Xie, J Pu, Z Shen, A Wang, T Li… - Oncogene, 2024 - nature.com
Doxorubicin and platinum are widely used in the frontline treatment of osteosarcoma, but
resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 …
resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 …
M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma.
M He, Y Wang, J Xie, J Pu, Z Shen, A Wang, T Li… - Oncogene, 2023 - europepmc.org
Doxorubicin and platinum are widely used in the frontline treatment of osteosarcoma, but
resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 …
resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 …
M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma
M He, Y Wang, J Xie, J Pu, Z Shen, A Wang… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Doxorubicin and platinum are widely used in the frontline treatment of osteosarcoma, but
resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 …
resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 …